<DOC>
	<DOCNO>NCT00117637</DOCNO>
	<brief_summary>The purpose study : - Find patient receive BAY43-9006 live longer without tumor progression receive standard therapy interferon alpha-2a - Find high dose BAY43-9006 inhibit tumor progression patient progressed standard dose treatment BAY43-9006 , long patient live without progression - Find long patient live without progression receive BAY43-9006 fail respond standard therapy interferon alpha-2a - Find many percent patient BAY43-9006 prevents growth shrink kidney tumor and/or metastasis depend treatment dosage - Find BAY43-9006 effect quality life patient kidney cancer - Find level BAY43-9006 blood per month change level - Find whether BAY43-9006 effect associate specific biomarkers</brief_summary>
	<brief_title>BAY43-9006 ( Sorafenib ) Versus Interferon Alpha-2a Patients With Unresectable and/or Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>Analyses Biomarkers exploratory assess tertiary objective trial .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients give write informed consent prior study specific screen procedure understand patient right withdraw study time , without prejudice Male female patient &gt; = 18 year age Patients life expectancy least 12 week Patients , suffer unresectable and/or metastatic , measurable predominantly clear cell RCC ( Renal Cell Carcinoma ) histologically cytologically documented Patients must undergo prior ( time primary diagnosis ) complete surgical excision primary RCC tumor Patients must prior systemic therapy advance RCC . Prior systemic therapy define treatment chemotherapy agent ( regimen ) , immunotherapy agent ( regimen ) investigational treatment agent ( regimen ) renal cell carcinoma . Megestrol acetate medroxyprogesterone constitute prior systemic therapy Patients least one unidimensional measurable lesion CT ( Computed tomography ) scan MRI ( Magnetic resonance imaging ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 7 day prior screen Hemoglobin &gt; 9.0 g/l Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelets &gt; = 100,000/ul Total bilirubin &lt; 1.5 x upper limit normal ALT ( Alanine aminotransferase ) AST ( Aspartate aminotransferase ) &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) Amylase lipase &lt; 1.5 x upper limit normal Serum creatinine &lt; 2.0 x upper limit normal PT ( Prothrombin Time ) INR ( International Normalized Ratio ) PTT ( Partial Thromboplastin Time ) &lt; 1.5 x upper limit normal ( patient receive anticoagulation treatment agent warfarin heparin allow participate . For patient warfarin , close monitoring least weekly evaluation perform INR stable base measurement pre dose , define local standard care ) Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta [ Noninvasive papillary carcinoma ] , Tis [ Carcinoma situ : `` flat tumor '' ] &amp; T1 [ Tumor invade subepithelial connective tissue ] ) cancer curatively treat &gt; 5 year prior study entry Complete renal shutdown require hemo peritoneal dialysis History cardiac disease : congestive heart failure &gt; NYHA ( New York Heart Association ) class 2 : active cardiovascular disease ( MI ( Distant metastasis ) 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension Active clinically serious bacterial fungal infection ( &gt; = grade 2 NCICTCAE ( National Cancer InstituteCommon Terminology Criteria Adverse Events ) , Version 3 ) Known history human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect brain tumour site time study entry . Also patient must undergo acute steroid therapy taper ( chronic steroid therapy acceptable provide dose stable one month prior follow screen radiographic study ( head CT MRI screen always require ) Patients seizure disorder require medication ( steroid antiepileptic ) History organ allograft Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardise safety patient his/her compliance study Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>RCC</keyword>
	<keyword>Cancer</keyword>
</DOC>